According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours.
Oseltamivir hard capsules and Tamiflu suspension are bioequivalent formulations. 75 mg doses can be administered as either
– one 75 mg capsule or
– one 30 mg capsule plus one 45 mg capsule or
– by administering one 30 mg dose plus one 45 mg dose of suspension.
Commercially manufactured Tamiflu powder for oral suspension (6 mg/ml) is the preferred product for paediatric and adult patients who have difficulties swallowing capsules or where lower doses are needed.
Adults, and adolescents 13 years and over
Treatment : The recommended oral dose is 75 mg oseltamivir twice daily for 5 days for adolescents (13 to 17 years of age) and adults.
Aggravation of diabetes
Toxic epidermal necrolysis
Swelling of face or tongue
Diaper rash (2 weeks to <1 year of age)
Abnormal liver function tests.